首页> 外文期刊>Journal of neuro-oncology. >Prospective study of stereotactic radiosurgery without whole brain radiotherapy in patients with four or less brain metastases: incidence of intracranial progression and salvage radiotherapy.
【24h】

Prospective study of stereotactic radiosurgery without whole brain radiotherapy in patients with four or less brain metastases: incidence of intracranial progression and salvage radiotherapy.

机译:有四个或更少脑转移的患者不进行全脑放疗的立体定向放射外科的前瞻性研究:颅内进展和抢救性放疗的发生率。

获取原文
获取原文并翻译 | 示例
       

摘要

This prospective study was conducted to evaluate the treatment outcome after stereotactic radiosurgery (SRS) alone with special attention to its influence on intracranial freedom from progression (FFP), local control, time to whole brain radiotherapy (WBRT), and survival. Forty-one patients with brain metastases who met the inclusion criteria were enrolled in this prospective cohort and treated by SRS alone between January 1998 and September 2001. The overall local control rate was 76%. The one year actuarial intracranial FFP was 33%. Ten patients (24%) had relapse at treated site. Twenty-three patients (56%) had intracranial progression with a median time of 4.25 months (1-24.6). Salvage radiotherapy was given in 21 patients (51%). Only 12 (29%) patients required WBRT with the median time to WBRT after SRS of 4.85 months. Nine patients (22%) underwent additional SRS at the median time of 5 months after the first procedure. The median survival was 10 months. At the time of follow up, 16 patients (39%) were still alive with a range of 6-31 months. This prospective study suggests that the omission of WBRT in the initial treatment of patients with SRS for four or less brain metastases may allow up to 70% of patients to avoid WBRT.
机译:这项前瞻性研究旨在评估仅采用立体定向放射外科手术(SRS)后的治疗结果,尤其要注意其对颅内脱离进展(FFP),局部控制,全脑放射治疗时间(WBRT)和存活率的影响。在1998年1月至2001年9月之间,有41位符合纳入标准的脑转移患者参加了这项前瞻性队列研究,仅通过SRS进行了治疗。总体局部控制率为76%。一年精算颅内FFP为33%。十名患者(24%)在治疗部位复发。 23例患者(56%)颅内进展,中位时间为4.25个月(1-24.6)。 21例(51%)进行了挽救性放疗。仅12名(29%)患者需要WBRT,SRS后达到4.8个月的中位时间为WBRT。首次手术后5个月的中位时间有9名患者(22%)接受了额外的SRS。中位生存期为10个月。在随访时,有16名患者(39%)仍然存活,生存时间为6-31个月。这项前瞻性研究表明,在SRS患者初次治疗中有四个或更少的脑转移病患者省略WBRT可能使多达70%的患者避免WBRT。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号